- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S Approval of Wegovy™ in the United States Investor Call Transcript
Hello, and welcome to the Novo Nordisk A/S conference call. (Operator Instructions) Today, I'm pleased to present Karsten Munk Knudsen. Please go ahead with your meeting.
/- -
Thank you. Welcome to the Novo Nordisk investor conference call covering the approval of semaglutide 2.4 in the U.S. now known under the brand name of Wegovy. My name is Karsten Munk Knudsen. I'm the CFO of Novo Nordisk. And today, with me, I have EVP of Commercial Strategy & Corporate Affairs, Camilla Sylvest; and EVP of Development, Martin Lange.
We will be doing a brief presentation followed by a Q&A, where we will only do 1 question per person since we have a fairly short time period today.
So today, we also might run into forward-looking statements. And as you know, by their very nature, these statements are subject to risks and uncertainties, and final outcomes might turn out differently.
The starting point for the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |